Compare BGI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGI | NXL |
|---|---|---|
| Founded | 1879 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 18.6M |
| IPO Year | 2005 | 2022 |
| Metric | BGI | NXL |
|---|---|---|
| Price | $1.04 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 28.0K | ★ 113.8K |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,846,182.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $0.56 | $0.70 |
| 52 Week High | $2.03 | $4.19 |
| Indicator | BGI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 32.08 |
| Support Level | $1.00 | $0.93 |
| Resistance Level | $1.09 | $1.01 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 20.32 | 6.84 |
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.